Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer

U. Bharadwaj, T. K. Eckols, M. Kolosov, M. M. Kasembeli, A. Adam, D. Torres, X. Zhang, L. E. Dobrolecki, W. Wei, M. T. Lewis, Bhuvanesh Dave, Jenny C. Chang, M. D. Landis, C. J. Creighton, M. A. Mancini, D. J. Tweardy

Research output: Contribution to journalArticle

89 Scopus citations

Abstract

Signal transducer and activator of transcription (STAT) 3 regulates many cardinal features of cancer including cancer cell growth, apoptosis resistance, DNA damage response, metastasis, immune escape, tumor angiogenesis, the Warburg effect and oncogene addiction and has been validated as a drug target for cancer therapy. Several strategies have been used to identify agents that target Stat3 in breast cancer but none has yet entered into clinical use. We used a high-throughput fluorescence microscopy search strategy to identify compounds in a drug-repositioning library (Prestwick library) that block ligand-induced nuclear translocation of Stat3 and identified piperlongumine (PL), a natural product isolated from the fruit of the pepper Piper longum. PL inhibited Stat3 nuclear translocation, inhibited ligand-induced and constitutive Stat3 phosphorylation, and modulated expression of multiple Stat3-regulated genes. Surface plasmon resonance assay revealed that PL directly inhibited binding of Stat3 to its phosphotyrosyl peptide ligand. Phosphoprotein antibody array analysis revealed that PL does not modulate kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyrosine kinases. PL inhibited anchorage-independent and anchorage-dependent growth of multiple breast cancer cell lines having increased pStat3 or total Stat3, and induced apoptosis. PL also inhibited mammosphere formation by tumor cells from patient-derived xenografts. PL's antitumorigenic function was causally linked to its Stat3-inhibitory effect. PL was non-toxic in mice up to a dose of 30 mg/kg/day for 14 days and caused regression of breast cancer cell line xenografts in nude mice. Thus, PL represents a promising new agent for rapid entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.

Original languageEnglish (US)
Pages (from-to)1341-1353
Number of pages13
JournalOncogene
Volume34
Issue number11
DOIs
StatePublished - Mar 12 2015

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer'. Together they form a unique fingerprint.

Cite this